These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38668039)

  • 1. Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement.
    Sehdev SR; Rawson NSB; Aseyev OI; Buick CJ; Butler MO; Edwards S; Gill S; Gotfrit JM; Hsia CC; Juergens RA; Manna M; McCarthy JS; Mukherjee SD; Snow SL; Spadafora S; Stewart DJ; Wentzell JR; Wong RPW; Zalewski PG
    Curr Oncol; 2024 Mar; 31(4):1803-1816. PubMed ID: 38668039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?
    Lau CY; Rawson NSB
    Curr Oncol; 2024 Sep; 31(9):5599-5607. PubMed ID: 39330042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.
    Rawson NSB; Stewart DJ
    Clinicoecon Outcomes Res; 2024; 16():437-445. PubMed ID: 38812711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action.
    Sehdev S; Gotfrit J; Elias M; Stein BD
    Curr Oncol; 2024 Mar; 31(3):1460-1469. PubMed ID: 38534943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canadian Contraception Consensus (Part 1 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
    J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health.
    Balijepalli C; Gullapalli L; Joshy J; Rawson NS
    J Comp Eff Res; 2024 May; 13(5):e230178. PubMed ID: 38567953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early access for innovative oncology medicines: a different story in each nation.
    Cowling T; Nayakarathna R; Wills AL; Tankala D; Paul Roc N; Barakat S
    J Med Econ; 2023; 26(1):944-953. PubMed ID: 37466223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada.
    Gotfrit J; Shin JJW; Mallick R; Stewart DJ; Wheatley-Price P
    Oncologist; 2020 Jan; 25(1):e130-e137. PubMed ID: 31506392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada.
    MacPhail C; Snow S
    Curr Oncol; 2022 Mar; 29(3):2064-2072. PubMed ID: 35323366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choosing Wisely Canada cancer list: ten low-value or harmful practices that should be avoided in cancer care.
    Mitera G; Earle C; Latosinsky S; Booth C; Bezjak A; Desbiens C; Delouya G; Laing K; Camuso N; Porter G
    J Oncol Pract; 2015 May; 11(3):e296-303. PubMed ID: 25980018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.
    Binder L; Ghadban M; Sit C; Barnard K
    Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment.
    Ho C; Lim HJ; Regier DA
    Curr Oncol; 2022 Jan; 29(2):402-410. PubMed ID: 35200536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
    Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
    Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board.
    Kuruvilla J; Assouline S; Hodgson D; MacDonald D; Stewart D; Christofides A; Komolova M; Connors J
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):59-74. PubMed ID: 25195028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.